diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 329db7879..0f4ccd475 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems. + +### Additional Evidence (extend) +*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16* + +WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence.' The conditional framing and requirement that countries consider 'local cost-effectiveness, budget impact, and ethical implications' suggests even the global health authority recognizes uncertainty about the chronic use economics and long-term value proposition. + --- Relevant Notes: diff --git a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md index eae369d26..0f65a7401 100644 --- a/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md +++ b/domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md @@ -41,6 +41,12 @@ The Commonwealth Fund's 2024 Mirror Mirror international comparison provides the The NHS paradox—ranking 3rd overall while having catastrophic specialty access—provides supporting evidence that medical care's contribution to health outcomes is limited. A system can have multi-year waits for specialty procedures yet still rank highly in overall health system performance because primary care, equity, and universal coverage (which address behavioral and social factors) matter more than specialty delivery speed for population health outcomes. + +### Additional Evidence (confirm) +*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16* + +WHO's three-pillar framework for GLP-1 obesity treatment explicitly positions medication as one component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies. WHO states obesity is a 'societal challenge requiring multisectoral action — not just individual medical treatment,' directly supporting the view that medical intervention alone cannot address health outcomes dominated by behavioral and social factors. + --- Relevant Notes: diff --git a/inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md b/inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md index c3c731b66..592d80456 100644 --- a/inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md +++ b/inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md @@ -7,9 +7,13 @@ date: 2025-12-01 domain: health secondary_domains: [] format: policy -status: unprocessed +status: enrichment priority: medium tags: [glp-1, WHO, global-health, obesity, guidelines, equity] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -39,3 +43,10 @@ WHO issued conditional recommendations for GLP-1 medicines in obesity treatment PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] WHY ARCHIVED: WHO's three-pillar framework challenges the pharmacological solution narrative and supports the view that GLP-1s are most effective when embedded in structural prevention infrastructure EXTRACTION HINT: The WHO position supports the BALANCE model's design but questions whether pharmaceutical solutions alone can address the obesity epidemic + + +## Key Facts +- WHO issued conditional (not full) recommendations for GLP-1 medicines in obesity treatment in December 2025 +- WHO framework has three pillars: population-level policies, high-risk protection, and person-centered care +- WHO emphasizes GLP-1s should be part of comprehensive approach including diet, physical activity, and professional support +- WHO guidelines have limited enforcement power but significant influence on national health policies, especially in low/middle-income countries